multicenter als imaging study

Conditions: Amyotrophic Lateral Sclerosis; ALS

Summary: this is a multi-site study of als participants and healthy controls who will undergo brain and cervical spine mris and nfl blood testing at up-to 4 time points over the course of a year. the primary goal is to identify objective biomarkers of disease progression that are biologically relevant, linearly progressive, and sensitive to change.

recent developments in magnetic resonance imaging (mri), biophysical modeling, and computing have improved the sensitivity of imaging metrics to detect disease-related changes in the central nervous system in neurological disorders. this improved sensitivity has paved the way for utilizing these metrics as potential biomarkers of disease, in particular, to measure disease progression over short durations. the investigators hypothesize that the multimodal analysis of mri biomarkers (microstructure and morphology) from the brain and spine will improve sensitivity to detect disease-related changes over durations as short as 3 to 6 months. the hypothesis is based on prior work detecting longitudinal changes in brain microstructure over 6 months in an als cohort with modest change in functional measures over that time, and that a multimodal analysis combining brain and spine mri measures can improve disease diagnosis accuracy. in this project, the investigators will establish the scalability, sensitivity over shorter durations, and overall clinical trial readiness of these metrics through a three-site study. the investigators also propose to improve the sensitivity of imaging metrics by combining multiple complementary measures from the brain and spine in a longitudinal multimodal statistical framework. additionally, the investigators will demonstrate how these imaging metrics correlate with fluid biomarkers and functional progression measures. upon completion of the project, the investigators anticipate that the enhanced sensitivity of our proposed longitudinal mri biomarkers will have an impact on als treatment by providing novel surrogate markers as potential outcome measures for clinical trials. the expected increased effect size will also reduce the cohort size needed to conduct trials, thereby increasing their feasibility. beyond the scope of clinical trials, these multimodal mri biomarkers will serve as an objective measure of upper motor neuron degeneration at the single patient level. the mri measures will also be cross validated with fluid biomarkers and will contribute to efforts to stratify als patients into clinically homogeneous cohorts. participants will be asked to complete 4 study visits over a 12-month period, with visits at baseline, 3 months, 6 months, and 12 months. participants will receive an exam by a neurologist, blood draw, and mri scan and will be asked to answer surveys about their medical history and als symptoms. participants will be compensated for each visit via a prepaid card. non-local participants living ≥100 miles from the research facility will be partially compensated for travel.

Eligibility criteria:
inclusion criteria: * \< 24 months since onset of symptoms * definite, probable, laboratory-supported probable, or possible als by el escorial criteria or definite, probable, or possible als by awaji-shima criteria * forced vital capacity within the last 90 days ≥ 60% of the predicted value * able to consent for themselves * able to read and speak english * clear of any contraindications for mri exclusion criteria: * individuals will be excluded if they have any condition that makes mri unsafe or if they are unable to comply with instructions. * all participants will undergo a neurologic examination at enrollment. control participants with clinically significant abnormal findings on neurological examination will be excluded from the study.

Keywords: magnetic resonance imaging mri alsfrs-r ecas plasma neurofilament light nfl